Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Differential pattern of CD4+ and CD8+ T-cell immunity to MAGE-A1/A2/A3 in patients with monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma.

Blood - 15 Oct 2008

Goodyear Oliver C, Pratt Guy, McLarnon Andrew, Cook Mark, Piper Karen, Moss Paul

Abstract excerpt

The factors that determine progression from monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma are unclear but may include the breakdown of immune surveillance. Cancer testis antigens (CTAgs) are expressed by the majority of myelomas and MGUS tumors and are a potential immune target. We have characterized CD4(+) and CD8(+) T-cell immune responses to MAGE-A1/A2/A3 in these patients....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, Neoplasm
Share to CD8-Positive T-Lymphocytes

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Immunologic Memory

Share to Immunotherapy

Share to Leukocyte Common Antigens

Share to Multiple Myeloma

Share to Paraproteinemias

Share to Receptors, CCR7

Source

Identifiers

PMID: 18658027
DOI: 10.1182/blood-2008-04-149393

Genes

CCR7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Differential pattern of CD4+ and CD8+ T-cell immunity to MAGE-A1/A2/A3 in patients with monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma.PMID 18658027Read ↗

T-Cell Characteristics Impact Response and Resistance to T-Cell–Redirecting Bispecific Antibodies in Multiple MyelomaSemantic proximity Read ↗

CD8+T cells specific for cancer germline gene antigens are found in many patients with multiple myeloma, and their frequency correlates with disease burdenSemantic proximity Read ↗

Mass Cytometry Discovers Two Discrete Subsets of CD39−Treg Which Discriminate MGUS From Multiple MyelomaSemantic proximity Read ↗

Immune Phenotypes and Target Antigens of Clonally Expanded Bone Marrow T Cells in Treatment-Naïve Multiple Myeloma.Semantic proximity Read ↗

Multiple Myeloma Cells Resistant to T-cell Therapies Exhibit a CD45+ Immunoevasive Phenotype.Semantic proximity Read ↗

The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patientsSemantic proximity Read ↗

CAR T-cell therapy in multiple myeloma: mission accomplished?Semantic proximity Read ↗

CARving a Path Forward: Unveiling T Cell Phenotypes Across the Spectrum of Multiple Myeloma Disease Progression to Inform Future Strategies for Overcoming Resistance to CAR T Therapy.Semantic proximity Read ↗

Determinants of Response and Mechanisms of Resistance of CAR T-cell Therapy in Multiple MyelomaSemantic proximity Read ↗

MAGE‐C1/CT‐7 expression in plasma cell myeloma: Sub‐cellular localization impacts on clinical outcomeSemantic proximity Read ↗

Mechanisms of resistance to CAR-T cell therapy in multiple myeloma: latest updates from the 2024 ASH annual meetingSemantic proximity Read ↗

Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistanceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.